Harrow Health Inc
NASDAQ:HROW

Watchlist Manager
Harrow Health Inc Logo
Harrow Health Inc
NASDAQ:HROW
Watchlist
Price: 44.77 USD -2.04% Market Closed
Market Cap: 1.7B USD

Operating Margin
Harrow Health Inc

11.2%
Current
1%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
11.2%
=
Operating Profit
28m
/
Revenue
250m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Harrow Health Inc
NASDAQ:HROW
1.7B USD
11%
US
Eli Lilly and Co
NYSE:LLY
997.2B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
503.6B USD
27%
CH
Roche Holding AG
SIX:ROG
255.1B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP
24%
CH
Novartis AG
SIX:NOVN
206.2B CHF
33%
US
Merck & Co Inc
NYSE:MRK
244.4B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
145.2B USD
29%
No Stocks Found

Harrow Health Inc
Glance View

Nestled within the bustling world of pharmaceutical innovation, Harrow Health Inc. emerges as a dynamic player with a distinctive business model tailored to transforming ophthalmic healthcare. With its roots planted firmly in the field of eye care, Harrow Health has mastered the art of compounding pharmaceuticals, focusing on delivering affordability and accessibility. The company operates primarily through its subsidiary, ImprimisRx, a compounding pharmacy that serves a robust network of ophthalmologists and optometrists across the United States. ImprimisRx’s unique approach involves creating custom-formulated medications tailored to specific patient needs, often at prices more competitive than traditional offerings. By prioritizing the compounding of prescription medications in its expansive network of accredited pharmacies, Harrow Health crafts a niche in the high-demand ophthalmology sector. Central to Harrow Health’s business strategy is its ability to capitalize on inefficiencies in the traditional drug market. By emphasizing a direct-to-prescriber model, the company circumvents many of the traditional barriers and costs associated with large pharmaceutical firms. This allows for a reduction in drug prices and improves distribution efficiency. Moreover, Harrow Health’s focus extends beyond compounding; it is actively involved in acquiring and licensing innovative ophthalmic technologies and products, constituting a broader ecosystem within eye care. This multi-pronged approach not only drives revenue through direct sales but also strengthens its position in the healthcare sector by investing in emerging therapies and expanding its reach in the marketplace. Such strategic maneuvers allow Harrow Health to sustain its growth trajectory while continuing to champion patient-centered care.

HROW Intrinsic Value
66.35 USD
Undervaluation 33%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
11.2%
=
Operating Profit
28m
/
Revenue
250m
What is the Operating Margin of Harrow Health Inc?

Based on Harrow Health Inc's most recent financial statements, the company has Operating Margin of 11.2%.

Back to Top